BR0307974A - Composição anti-parasita - Google Patents

Composição anti-parasita

Info

Publication number
BR0307974A
BR0307974A BR0307974-0A BR0307974A BR0307974A BR 0307974 A BR0307974 A BR 0307974A BR 0307974 A BR0307974 A BR 0307974A BR 0307974 A BR0307974 A BR 0307974A
Authority
BR
Brazil
Prior art keywords
closantel
parasites
animal
treated
group
Prior art date
Application number
BR0307974-0A
Other languages
English (en)
Other versions
BR0307974B1 (pt
Inventor
William Blakely
Lilian Cromie
Sean Duffy
Original Assignee
Norbrook Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norbrook Lab Ltd filed Critical Norbrook Lab Ltd
Publication of BR0307974A publication Critical patent/BR0307974A/pt
Publication of BR0307974B1 publication Critical patent/BR0307974B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

"COMPOSIçãO ANTI-PARASITA". Uma composição preparada para o tratamento de animais sofrendo de parasitas, cujos parasitas são conhecidos como sendo suscetíveis a pelo menos uma das avermectinas, milbemicinas ou salicilanilidas, que compreende, por exemplo, ivermectina em uma quantidade de 0, 1 a 10% (peso/volume), um solvente escolhido do grupo consistindo de formal glicerol, propileno glicol, polietileno glicol e combinações dos mesmos, e uma salicilanilida como closantel em uma quantidade de dosagem requerida para o animal a ser tratado, tipicamente em torno de 2,5 mg/kg de peso vivo do animal a ser tratado, uma espécie polimérica escolhida do grupo consistindo de polivinil pirrolidona e copolímeros em bloco de polioxipropileno/polioxietileno, as referidas especies poliméricas melhorando a biodisponibilidade do closantel até o ponto em que são obteníveis níveis de plasma do sangue do referido composto maiores do que cerca de 20 ppm ao longo do período de tratamento.
BRPI0307974-0B1A 2002-02-28 2003-02-12 “composição parasiticida de ação prolongada contendo um composto de salicilanilida, uma espécie polimérica e pelo menos um outro composto antiparasita” BR0307974B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0204712.4 2002-02-28
GB0204712A GB2386066A (en) 2002-02-28 2002-02-28 Long-acting parasiticidal composition with improved bioavailability comprising a salicylanilide, a further anti-parasitic compound & a polymeric species
PCT/GB2003/000645 WO2003072113A1 (en) 2002-02-28 2003-02-12 Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound

Publications (2)

Publication Number Publication Date
BR0307974A true BR0307974A (pt) 2004-12-21
BR0307974B1 BR0307974B1 (pt) 2014-10-21

Family

ID=9931978

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0307974-0B1A BR0307974B1 (pt) 2002-02-28 2003-02-12 “composição parasiticida de ação prolongada contendo um composto de salicilanilida, uma espécie polimérica e pelo menos um outro composto antiparasita”

Country Status (23)

Country Link
US (1) US9289380B2 (pt)
EP (1) EP1478372B1 (pt)
JP (1) JP4480400B2 (pt)
AP (1) AP1977A (pt)
AR (1) AR038852A1 (pt)
AT (1) ATE347897T1 (pt)
AU (1) AU2003205887B2 (pt)
BR (1) BR0307974B1 (pt)
CA (1) CA2476520C (pt)
CO (1) CO5611154A2 (pt)
CR (1) CR7429A (pt)
CY (1) CY1107530T1 (pt)
DE (1) DE60310377T2 (pt)
DK (1) DK1478372T3 (pt)
EC (1) ECSP045320A (pt)
ES (1) ES2275076T3 (pt)
GB (1) GB2386066A (pt)
MX (1) MXPA04007996A (pt)
NZ (1) NZ534704A (pt)
PT (1) PT1478372E (pt)
SI (1) SI1478372T1 (pt)
WO (1) WO2003072113A1 (pt)
ZA (1) ZA200406782B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002952597A0 (en) * 2002-11-11 2002-11-28 Schering-Plough Pty. Limited Topical parasiticide formulations and methods of treatment
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
ATE404175T1 (de) * 2003-03-31 2008-08-15 Alza Corp Nicht wässrige einphasige visköse vehikel und formulierungen die diese vehikel verwenden
US7666444B2 (en) 2004-02-02 2010-02-23 Wyeth Antiparasitic composition
WO2006061214A1 (en) * 2004-12-10 2006-06-15 Bayer Healthcare Ag Anthelmintic composition
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
DK2359808T3 (da) 2006-08-09 2013-08-05 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelaggregater
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
LT2462246T (lt) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
FR2991173B1 (fr) 2012-06-04 2015-11-06 Virbac Composition veterinaire a administration cutanee a base d'oxyclozanide
WO2015048371A1 (en) * 2013-09-30 2015-04-02 Zoetis Llc Long-acting spiro-isoxazoline formulations
JP2017529393A (ja) 2014-09-12 2017-10-05 アンティバイオティクス エーピーエスＡｎｔｉｂｉｏｔｘ Ａｐｓ ハロゲン化サリチルアニリドの抗菌用途
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
GB201604484D0 (en) * 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
EP3733694A1 (en) 2016-05-16 2020-11-04 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3950360A (en) 1972-06-08 1976-04-13 Sankyo Company Limited Antibiotic substances
DE2263509C2 (de) 1972-12-27 1981-12-24 Rudolf Dr. 6380 Bad Homburg Kürner Deodorant
US4005218A (en) 1975-03-18 1977-01-25 Janssen Pharmaceutica N.V. Antiparasitic salicylanilide derivatives
SE434277B (sv) 1976-04-19 1984-07-16 Merck & Co Inc Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis
US4206205A (en) 1977-10-03 1980-06-03 Merck & Co., Inc. Monosaccharide and aglycone derivatives of C-076
US4199569A (en) 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
US4173571A (en) 1977-12-19 1979-11-06 Merck & Co., Inc. 13-Halo and 13-deoxy derivatives of C-076 compounds
US4171314A (en) 1977-12-19 1979-10-16 Merck & Co., Inc. 13-Halo and 13-deoxy C-076 compounds
US4128632A (en) 1978-02-13 1978-12-05 Merck & Co., Inc. Solubilization of Rafoxanide
OA06863A (fr) 1980-08-04 1983-02-28 Merck & Co Inc Solubilisation de l'invermectine dans l'eau.
NZ210505A (en) 1983-12-22 1988-06-30 Merck & Co Inc Parasiticidal compositions containing avermectin or milbemycin derivatives
GB8727157D0 (en) * 1987-11-19 1987-12-23 Wellcome Found Pharmaceutical formulations
NZ223200A (en) * 1988-01-15 1989-01-06 Ancare Distributors Anthelmintic compositions containing 2',5-dicloro-4'-nitrosalicylanilide and non aqueous carrier
US5273805A (en) * 1991-08-05 1993-12-28 Minnesota Mining And Manufacturing Company Structured flexible carrier web with recess areas bearing a layer of silicone on predetermined surfaces
NZ335166A (en) 1999-04-14 2001-11-30 Ashmont Holdings Ltd Anthelmintic composition containing triclabendazole in at least one solvent
CN1054504C (zh) 1993-03-15 2000-07-19 科尔加特·帕尔莫利弗公司 洁牙剂
PL174488B1 (pl) 1993-05-10 1998-08-31 Merck & Co Inc Preparat do zwalczania pasożytów zwierząt oraz sposób wytwarzania preparatu do zwalczania pasożytów zwierząt
NZ267366A (en) 1993-06-15 1996-12-20 Univ Australian Controlling fasciola and other helminths using a synergistic composition of at least two anthelmintic active drugs each being selected from a different class of drug
NZ248486A (en) * 1993-08-24 1996-07-26 Ashmont Holdings Limited Subst Stable anthelmintic formulation containing closantel and one or more avermectins or milbemycins in a glycol based solvent
EP0734258A1 (en) 1993-12-13 1996-10-02 Michael Hilary Burke Anthelmintic composition containing rafoxanide and fenbendazole
FR2739778B1 (fr) 1995-10-13 1997-12-12 Virbac Lab Formulation topique destinee a traiter la maladie de la douve du foie chez l'animal
US5773422A (en) * 1996-01-29 1998-06-30 Komer; Gene Avermectin formulation
US6193989B1 (en) 1997-03-21 2001-02-27 Biogenesis S.A. Long acting injectable parasiticidal composition and the process for its preparation
US6340672B1 (en) 2000-02-16 2002-01-22 Phoenix Scientific, Inc. Parasiticidal formulation and a method of making this formulation
AUPQ875700A0 (en) * 2000-07-13 2000-08-03 Reflex Research Limited Combination compositions
AUPR510001A0 (en) * 2001-05-18 2001-06-14 Jupitar Pty Ltd Formulation and method

Also Published As

Publication number Publication date
EP1478372A1 (en) 2004-11-24
US20050118221A1 (en) 2005-06-02
ZA200406782B (en) 2005-07-27
ES2275076T3 (es) 2007-06-01
CA2476520C (en) 2009-08-11
CR7429A (es) 2006-02-06
AP1977A (en) 2009-03-19
ATE347897T1 (de) 2007-01-15
CY1107530T1 (el) 2013-03-13
DE60310377D1 (de) 2007-01-25
AU2003205887A1 (en) 2003-09-09
EP1478372B1 (en) 2006-12-13
CA2476520A1 (en) 2003-09-04
ECSP045320A (es) 2004-11-26
CO5611154A2 (es) 2006-02-28
DE60310377T2 (de) 2007-10-31
JP2005525355A (ja) 2005-08-25
JP4480400B2 (ja) 2010-06-16
DK1478372T3 (da) 2007-04-10
PT1478372E (pt) 2007-01-31
NZ534704A (en) 2007-02-23
AU2003205887B2 (en) 2007-02-15
WO2003072113A1 (en) 2003-09-04
BR0307974B1 (pt) 2014-10-21
GB2386066A (en) 2003-09-10
SI1478372T1 (sl) 2007-04-30
GB0204712D0 (en) 2002-04-17
AP2004003142A0 (en) 2004-09-30
AR038852A1 (es) 2005-01-26
MXPA04007996A (es) 2004-11-26
US9289380B2 (en) 2016-03-22

Similar Documents

Publication Publication Date Title
BR0307974A (pt) Composição anti-parasita
ATE209511T1 (de) Gezieltabbaubare medizinische geräte
ATE316786T1 (de) Behandlung von mukositis
ATE307611T1 (de) Flüssiges hochvisköses system mit gesteuerter freisetzung und medizinische oder chirurgische vorrichtung
BR0311978A (pt) Preparação, método para preparar a mesma, formulação farmacêutica, métodos para tratar de uma sìndrome responsiva ao fator vii, para prevenir hemorragias indesejáveis, para prevenir coagulação sanguìnea indesejável e para prevenir as reações mediadas pelo fator tecidual, e, uso de uma preparação
DK1664041T3 (da) Phenylcarboxamidforbindelser, der er egnede til behandling af smerter
DK1227126T3 (da) Gummisammensætning anvendt til en gummiprop til et medikament eller til en medicinsk behandling eller dets tævrbundne produkt
ATE477758T1 (de) Einweg-vorrichtung zur behandlung von infektionen der menschlichen extremitäten
DK3449934T3 (da) Behandling af glycogenlagringssygdom type II
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
ATE427760T1 (de) Erodierbare polymere zur injektion
BR9406059A (pt) Composição farmacéutica e método para tratamento de uma infecção helmintica em um animal
ECSP066360A (es) Composición parasiticida
EA200601249A1 (ru) Пиперазины, пригодные для лечения боли
AR038853A1 (es) Una composicion parasiticida inyectable
WO2005055956A3 (en) Method for improving insulin sensitivity by administering an inhibitor of antitrypsin
CU23351A3 (es) Composición parasiticidal de acción retardada conteniendo un compuesto salicieanilida, una especie polimérica y al menos otro compuesto anti-parasitario
AR037543A1 (es) Metodo para la terapia del cancer y composicion farmaceutica
DK0505389T3 (da) Antiparasitisk præparat til animalsk anvendelse
BR0308734A (pt) Composto, composição farmacêutica, uso do composto, e, método para prevenir ou tratar infecção
AR028470A1 (es) Ariltiofeno agonistas de vasopresina, el uso de los mismos para manufactura de un medicamento y composicion farmaceutica
EA200400965A1 (ru) Способ лечения или профилактики желудочно-кишечных заболеваний (варианты), антимикробная композиция (варианты)
ATE329613T1 (de) Wachstumhormone inhibitoren enthaltende pharmazeutische zubereitungen oder ihre biologisch aktive fragmente zur behandlung von uterinen myomas
TH85262B (th) "สารผสมหลอดสวนและการใช้สิ่งนั้น"
CO5080781A1 (es) Combinacions de herbicidas y antidotos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/7048, 31/277, 47/32; A61P 33/00, 33/10, 33/14

Ipc: A61K 31/7048 (2011.01), A61K 31/277 (2011.01), A61

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/10/2014, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time
B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)